Cost-Effectiveness of Risk-Stratified Colorectal Cancer Screening Based on Polygenic Risk: Current Status and Future Potential.

Steffie K NaberSuman KunduKaren M KuntzW David Dotson Marc S WilliamsAnn G ZauberNed CalongeDoris T ZallenTheodore G GaniatsElizabeth M WebberKatrina A B GoddardNora B HenriksonMarjolein van BallegooijenA Cecile J W JanssensIris Lansdorp-Vogelaar

Published in: JNCI cancer spectrum (2019)

Currently, CRC screening based on polygenic risk is unlikely to be cost-effective compared with uniform screening. This is expected to change with a greater than 0.05 increase in AUC value, a greater than 30% reduction in polygenic testing costs, or a greater than 5% increase in adherence with screening.

Keyphrases

colorectal cancer screening
type diabetes
risk assessment
climate change
adipose tissue
skeletal muscle
weight loss
glycemic control
human health